Emmes, a United States-based full-service Clinical Research Organisation, announced on Monday1, that it has named Dr Paul VanVeldhuisen as the president of Emmes Public Sector.
Dr VanVeldhuisen has more than 25 years of experience in clinical research. He joined Emmes in 1993 and later became a principal investigator. He has held roles of increasing responsibility in the company. Dr VanVeldhuisen has a PhD in epidemiology from The George Washington University, an MS in biostatistics from the University of Washington and a BS in mathematics from Calvin University.
POLYTECH Health & Aesthetics announces Poland expansion
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Clario acquires imaging provider NeuroRx
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval